ProfileGDS5678 / 1436097_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 89% 93% 90% 91% 92% 90% 90% 88% 90% 89% 87% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9560489
GSM967853U87-EV human glioblastoma xenograft - Control 27.1373789
GSM967854U87-EV human glioblastoma xenograft - Control 37.0239389
GSM967855U87-EV human glioblastoma xenograft - Control 48.1051793
GSM967856U87-EV human glioblastoma xenograft - Control 57.2397590
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1113291
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4300392
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1102290
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1095390
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8156488
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1555690
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0095889
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7135387
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9836989